Hypophosphatemia is recognized most often in critically-ill patients, decompensated diabetics, alcoholics or other malnourished persons, and acute infectious or pulmonary disorders.
A decrease in serum phosphate should be distinguished from a decrease in total body storage of phosphate.
Hypophosphatemia may be transient and reflect intracellular shift with minimal clinical consequences.
Most symptoms of acute hyperphosphatemia are due to secondary hypocalcemia.
The significant level of hyperphosphatemia in adults is 5 mg/dL.
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Consumption of glutinous brown rice (GBR) controls the whole-day glucose profile of patients with type 2 diabetes mellitus (T2DM), mainly by lowering postprandial glucose excursion, reports a study. In addition, GBR is preferred over nonglutinous brown rice (BR) in terms of palatability.
Use of dipeptidyl peptidase-4 (DPP-4) inhibitors may reduce the risk of mortality and the combination of myocardial infarction and ischaemic stroke in type 2 diabetes (T2D), without increasing the risk of hospitalisation for heart failure even in T2D patients with pre-existing HF, a nationwide cohort study from Taiwan suggests.